Answers are grounded in this paper and cite their sources.
Retrospective cohort study comparing FIB-4 changes in GLP-1RA-naïve versus GLP-1RA switch patients, indicating differential effects.
Objective Tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, has been shown to improve hepatic inflammation and steatosis in patients with type 2 diabetes. However, whether its effects on Fibrosis-4 (FIB-4), a surrogate marker of liver fibrosis, differ between patients naїve to GLP-1 receptor agonists (GLP-1RAs) and those who have switched from a GLP-1RA remains unclear.
No takes yet. Share an insight, caveat, or question.
Ito et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: